待处理
入排:排除
图源:待检查
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Li Ding, Bin Yang, Xudong Yao
Eur Urol 86(4) e88-e89
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板